Table 2.
Data regarding NENs received first-line chemotherapy.
| Chemotherapy regimens | Patients received first-line chemotherapy | Patients responded to first-line chemotherapy | In total | P-value | |
|---|---|---|---|---|---|
| Protruding (n=22) |
cisplatin/carboplatin+etoposide | 10 | 7 | 11 (50.0%) | 0.03 * |
| oxaliplatin+capecitabine/5-Fu | 5 | 1 | |||
| temozolomide + capecitabine | 1 | 0 | |||
| temozolomide + S-1 | 3 | 2 | |||
| irinotecan + S-1 | 1 | 1 | |||
| etoposide + thalidomide | 1 | 0 | |||
| AK105 + anlotinib | 1 | 0 | |||
| Ulcerative (n=25) |
cisplatin/carboplatin/oxaliplatin+etoposide | 11 | 3 | 5 (20.0%) | |
| oxaliplatin+capecitabine/5-Fu | 7 | 1 | |||
| temozolomide + capecitabine | 3 | 0 | |||
| irinotecan + capecitabine | 1 | 1 | |||
| cisplatin + irinotecan | 1 | 0 | |||
| oxaliplatin +fruquintinib | 1 | 0 | |||
| AK105 + anlotinib | 1 | 0 |
*The P-value refers to the comparison between response rates in protruding and ulcerative groups.